Liquidia Corporation’s stock took a significant hit after the FDA granted tentative approval to their drug YUTREPIA for treating pulmonary hypertension. The approval comes with a catch – regulatory exclusivity granted to United Therapeutics for Tyvaso DPI, which delays YUTREPIA’s full market entry until 2025. Liquidia plans to challenge this decision.
Jim Cramer shared his insights on various stocks on his ‘Mad Money’ show, including CloudFlare, Axon Enterprise, First Solar, Vista Energy, Crown Castle, Astera Labs, and Liquidia. He provided analysis and recommendations for each company, discussing their financial performance, growth prospects, and investment potential.
